OncoSec Medical to Present at Needham & Company’s 14th Annual Healthcare Conference
April 02 2015 - 6:00AM
Business Wire
OncoSec Medical Inc. (“OncoSec”) (OTCQB: ONCS), a company
developing DNA-based intratumoral cancer immunotherapies, announced
today that CEO and President Punit Dhillon will present a corporate
overview at Needham & Company’s 14th Annual Healthcare
Conference on Tuesday, April 14, 2015 in New York City. The
presentation is scheduled to begin at 8:40 AM ET at the Westin
Grand Central Hotel.
Each year, Needham’s Healthcare Conference features
presentations from approximately 100 companies in the
biotechnology, specialty pharmaceutical, medical technology and
diagnostic sectors. The conference focuses on connecting leading
public and private life science companies and investors. One-on-one
meetings with companies will be available for qualified
institutional investors and venture capital firms. For more
information, please visit: http://www.needhamco.com.
OncoSec invites investors and the general public to view and
listen to the live webcast. At the time of the presentation, the
webcast will be available via the following link:
http://wsw.com/webcast/needham71/oncs. Please register at least 10
minutes prior to the start of the presentation to ensure timely
access. After the presentation, an archived version of the webcast
will be available for 90 days on OncoSec’s website:
http://www.oncosec.com.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its investigational ImmunoPulse intratumoral cancer immunotherapy.
OncoSec’s core technology is designed to enhance the local delivery
and uptake of DNA IL-12 and other DNA-based immune-targeting
agents. Clinical studies of ImmunoPulse have demonstrated an
acceptable safety profile and preliminary evidence of anti-tumor
activity in the treatment of various skin cancers, as well as the
potential to initiate a systemic immune response limiting the
systemic toxicities associated with other treatments. OncoSec's
lead program evaluating ImmunoPulse for the treatment of metastatic
melanoma is currently in Phase II development, and is being
conducted in collaboration with several prominent academic medical
centers. As the company continues to evaluate ImmunoPulse in its
current indications, it is also focused on identifying and
developing new immune-targeting agents, investigating additional
tumor indications, and evaluating combination-based immunotherapy
approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
OncoSec Medical Inc.Investor Relations:Jordyn Kopin,
855-662-6732investors@oncosec.comorMedia Relations:Mary Marolla,
855-662-6732media@oncosec.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Aug 2024 to Sep 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Sep 2023 to Sep 2024